IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

Aggregated presentation by day and by market









Statement of transactions in own shares from July 21st to July 25th 2025
       
Name of the issuerIdentity code of the issuer

(Legal Entity Identifier) 		Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 350 106,16429AQEU
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 1 300 106,16408CCXE
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 250 106,14TQEX
IPSEN549300M6SGDPB4Z94P1121/07/2025FR0010259150 2 390 106,43301XPAR
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 300 105,20AQEU
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 1 000 105,20CCXE
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 300 104,96667TQEX
IPSEN549300M6SGDPB4Z94P1122/07/2025FR0010259150 3 000 105,51353XPAR
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 200 108,645AQEU
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 300 108,06667CCXE
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 200 108,00TQEX
IPSEN549300M6SGDPB4Z94P1123/07/2025FR0010259150 2 400 108,13342XPAR
IPSEN549300M6SGDPB4Z94P1124/07/2025FR0010259150 650 111,86154CCXE
IPSEN549300M6SGDPB4Z94P1124/07/2025FR0010259150 150 111,93333TQEX
IPSEN549300M6SGDPB4Z94P1124/07/2025FR0010259150 3 252 111,77211XPAR
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 280 111,50821AQEU
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 980 111,64612CCXE
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 200 111,52TQEX
IPSEN549300M6SGDPB4Z94P1125/07/2025FR0010259150 3 143 111,67378XPAR
   TOTAL20 645 108,6488 

Attachment



EN
29/07/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

7h / 28m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

7h / 28m 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch